MiddleBrook brings in Morgan Stanley for review

MiddleBrook Pharmaceuticals has brought in Morgan Stanley to advise the company on its strategic alternatives, including a possible sale of the company. MiddleBrook, which develops anti-infectives, says the review will cover everything from staying on its present course to inking new collaborations and selling assets. Executives of the developer--formerly known as Advancis--first announced the company was undergoing a strategic review last spring. The FDA approved its resubmitted application for a strep throat remedy in January.

- see MiddleBrook's release
- read the AFX story

Suggested Articles

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.

Early data out of former Fierce 15 winner Gritstone Oncology have been heralded as a big win for the early-stage biotech by analysts.

Biogen will drop work on gosuranemab in progressive supranuclear palsy but continue on in Alzheimer's.